Lantheus (NASDAQ:LNTH) Updates FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 6.650-6.700 for the period, compared to the consensus earnings per share estimate of 6.750. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Lantheus Stock Performance

Shares of LNTH opened at $91.13 on Wednesday. The stock has a 50 day moving average price of $91.78 and a two-hundred day moving average price of $100.12. The firm has a market capitalization of $6.34 billion, a P/E ratio of 15.16 and a beta of 0.46. Lantheus has a 52 week low of $51.79 and a 52 week high of $126.89.

Analyst Ratings Changes

Several equities analysts have recently issued reports on LNTH shares. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.